Adaptive NK cells mediate antibody-dependent cellular cytotoxicity (ADCC) in multiple myeloma and can be improved by treatment with anti-CD38 mAbs, such as daratumumab and isatuximab (50). This evidence concerns the gene CD38 and AL amyloidosis.